Kevin Onyango

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis et al. · The Lancet Respiratory Medicine · 2023 · 96 citations · Full text

Pharmacy, Pharmacotherapy, Antimicrobial Pharmacotherapy +12

Prevention of HIV-1 Infection with Early Antiretroviral Therapy for the HPTN 052 Study Team*

Myron S. Cohen, Ying Qing Chen, Marybeth McCauley et al. · 2011 · 86 citations

Public Health, Infectious Diseases, Preventive Medicine +16

Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results

Ruanne V. Barnabas, Elizabeth R. Brown, Maricianah Onono et al. · Nature Medicine · 2023 · 86 citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study

Bernhards Ogutu, Kevin Onyango, Nelly Koskei et al. · Malaria Journal · 2014 · 57 citations · Full text

Medicine, Pediatrics, Pharmacology +17

Comparison of artesunate–mefloquine and artemether–lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial

Sodiomon B. Sirima, Bernhards Ogutu, John Lusingu et al. · The Lancet Infectious Diseases · 2016 · 52 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16